What is KPV

KPV is a naturally occurring tripeptide studied in research for its incredibly potent anti-inflammatory and immunomodulatory properties. It is intended exclusively for research use.

Regarding its chemical identity, KPV has a molecular formula of C17H31N5O4 and a molecular weight of 369.5 g/mol. Its reported canonical sequence is Lys-Pro-Val. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include KPV.

Product for research use.

Mechanism of action of KPV

KPV exerts its anti-inflammatory effects by entering the cell and directly interacting with inflammatory signaling pathways, specifically inhibiting the activation of NF-kB. This halts the production of pro-inflammatory cytokines inside the cell before they can cause tissue damage.

Pharmacokinetics and pharmacodynamics of KPV

As a tiny tripeptide, KPV is rapidly absorbed and highly systemic, easily crossing cellular membranes and the blood-brain barrier. It has a short half-life but exerts profound genetic down-regulation of inflammation that lasts significantly longer.

Scientific evidence on KPV

The available evidence on KPV is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Extensively investigated in models of inflammatory bowel disease (IBD), psoriasis, and systemic inflammatory response syndrome. Preclinical data shows it rivals traditional corticosteroids in reducing inflammation without the associated immunosuppressive side effects.

KPV applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

KPV protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for KPV, so no trial schemes or quantities are specified.

The presentations of this product (Various (e.g., 5MG, 10MG)) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of KPV

As a general guideline for laboratory handling, lyophilized peptides such as KPV are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the Various (e.g., 5MG, 10MG) contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

KPV Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented KPV security profile

The documented safety information in open sources for KPV is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

KPV has a highly favorable theoretical safety profile. Because it is a natural fragment of the alpha-MSH hormone and acts as an immune normalizer rather than an immune suppressor, it does not carry the toxicological risks of chronic steroid use.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

KPV in a comparative context

KPV is the C-terminal fragment of alpha-MSH. Unlike its parent molecule, KPV does not cause skin pigmentation or arousal, isolating only the pure anti-inflammatory properties of the hormone. It is highly comparable to BPC-157 for gut healing but operates via a direct anti-inflammatory mechanism.

History and development of KPV

Isolated as researchers sought to identify the specific amino acid sequence responsible for the anti-inflammatory effects of the alpha-Melanocyte-Stimulating Hormone without triggering its melanogenic (tanning) effects.